LinYu

Linyu Biotech is a Shanghai-based biotechnology company specializing in the development of next-generation in vivo cell therapies. The company leverages a proprietary mRNA-LNP (lipid nanoparticle) delivery platform to reprogram cells directly within the patient's body, aiming to overcome the complexities and costs associated with traditional ex vivo CAR-T therapies. Their primary focus includes treating autoimmune diseases and various cancers by engineering immune cells in situ. Linyu Biotech has attracted significant investment from prominent venture capital firms to advance its pipeline toward clinical trials. The company's leadership includes experienced professionals from global pharmaceutical organizations, positioning it as a key player in the emerging field of in vivo cell engineering.